Royalty Pharma Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
MRKMerck & Co., Inc. -0.06%81.120.7%$1566.02m
JNJJohnson & Johnson 0.19%163.710.7%$997.82m
PFEPfizer Inc. 0.77%43.190.9%$901.42m
ABBVAbbVie, Inc. 0.42%109.221.9%$661.78m
BMYBristol-Myers Squibb Co. -0.38%57.591.0%$625.23m
LLYEli Lilly & Co. 1.07%243.751.1%$585.84m
AZNAstraZeneca Plc 0.93%61.791.0%$310.35m
NVSNovartis AG 0.31%84.930.2%$174.90m
GSKGlaxoSmithKline Plc 0.58%39.780.2%$162.05m
AVIRAtea Pharmaceuticals, Inc. -0.16%12.730.3%$125.28m
RGENRepligen Corp. 1.55%274.956.8%$113.28m
NVONovo Nordisk A/S 1.51%105.990.1%$89.92m
VTRSViatris, Inc. -0.50%13.940.0%$87.91m
SNYSanofi 1.44%49.920.2%$70.53m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.27%139.980.0%$52.50m

Company Profile

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.